Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 181.69% | Wedbush | $25 → $18 | Maintains | Outperform |
| 10/12/2023 | 181.69% | HC Wainwright & Co. | $20 → $18 | Maintains | Buy |
| 08/08/2023 | 291.24% | Wedbush | $26 → $25 | Maintains | Outperform |
| 08/08/2023 | 212.99% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 369.48% | Oppenheimer | → $30 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 306.89% | Wedbush | → $26 | Reiterates | → Outperform |
| 05/12/2023 | 212.99% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/28/2023 | 181.69% | Evercore ISI Group | → $18 | Initiates Coverage On | → Outperform |
| 02/24/2023 | 212.99% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 12/19/2022 | 212.99% | HC Wainwright & Co. | $13 → $20 | Maintains | Buy |
| 09/29/2021 | 212.99% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月13日 | 181.69% | 韦德布什 | $25→$18 | 维护 | 跑赢大盘 |
| 2023年10月12日 | 181.69% | HC Wainwright公司 | $20→$18 | 维护 | 买 |
| 2023/08/08 | 291.24% | 韦德布什 | $26→$25 | 维护 | 跑赢大盘 |
| 2023/08/08 | 212.99% | HC Wainwright公司 | →$20 | 重申 | 购买→购买 |
| 06/08/2023 | 369.48% | 奥本海默 | →$30 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月12日 | 306.89% | 韦德布什 | →$26 | 重申 | →跑赢大盘 |
| 2023年05月12日 | 212.99% | HC Wainwright公司 | →$20 | 重申 | 购买→购买 |
| 03/28/2023 | 181.69% | Evercore ISI集团 | →$18 | 开始承保 | →跑赢大盘 |
| 02/24/2023 | 212.99% | HC Wainwright公司 | →$20 | 重申 | →购买 |
| 2022年12月19日 | 212.99% | HC Wainwright公司 | $13→$20 | 维护 | 买 |
| 09/29/2021 | 212.99% | 杰富瑞 | →$20 | 开始承保 | →购买 |
What is the target price for Astria Therapeutics (ATXS)?
Astria Treeutics(ATXS)的目标价格是多少？
The latest price target for Astria Therapeutics (NASDAQ: ATXS) was reported by Wedbush on October 13, 2023. The analyst firm set a price target for $18.00 expecting ATXS to rise to within 12 months (a possible 181.69% upside). 10 analyst firms have reported ratings in the last year.
韦德布什于2023年10月13日报道了阿斯特里亚治疗公司(纳斯达克：ATXS)的最新目标价。这家分析公司将目标价定为18美元，预计ATXS将在12个月内上涨至(可能上涨181.69%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
Astria Treateutics(ATXS)的最新分析师评级是什么？
The latest analyst rating for Astria Therapeutics (NASDAQ: ATXS) was provided by Wedbush, and Astria Therapeutics maintained their outperform rating.
韦德布什公司提供了对阿斯特里亚治疗公司(纳斯达克代码：ATXS)的最新分析师评级，阿斯特里亚治疗公司维持了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Astria Treeutics(ATXS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查看公共财务报表，与Astria Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Astria治疗公司的上一次评级是在2023年10月13日提交的，所以你应该预计下一次评级将在2024年10月13日左右的某个时候提供。
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
分析师对Astria Treeutics(ATXS)的评级正确吗？
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $25.00 to $18.00. The current price Astria Therapeutics (ATXS) is trading at is $6.39, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Astria Treateutics(ATXS)评级保持不变，目标价在25.00美元至18.00美元之间。Astria Treateutics(ATXS)目前的交易价格为6.39美元，超出了分析师的预测区间。